LIB-01 completed phase 1 with strong safety and efficacy signals; phase 2a is fully funded and set for Q4 2024. A SEK 122.6 million rights issue is underway, with 65% secured, to support continued development and expansion into metabolic diseases.
Original document:
This is an AI-generated summary and may contain inaccuracies. Please verify any important information with the original source.